Using Serum Cholesterol To Identify High Risk and Stimulate Behavior Change: Will It Work?

References

• Oliver M. Coronary risk factors: should we not forget about mass control?. World Health Forum 1984; 5: 5–8
   Google Scholar
• Puska P., Salonen J. T., Tuomilehto J., Nissinen A., Koskela K. We have good reason to promote general risk factor reductions in whole populations. World Health Forum 1984; 5: 15–6
   Google Scholar
• Murray D. M., Luepker R. V., Pirie P. L., Grimm R. H., Bloom E., Davis M. A., Blackburn H. Systematic risk factor screening and education: a community‐wide approach to prevention of coronary heart disease. Prev Med 1986; 1: 661–72
   Google Scholar
• Martin M. J., Hulley S. B., Browner W. S., Kuller L. H., Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 1986; ii: 933–6
   Google Scholar
• Rose G., Shipley M. Plasma cholesterol concentration and death from coronary heart disease: 10 year results of the Whitehall study. Br Med J 1986; 293: 306–7
   PubMedGoogle Scholar
• Heller R. F., Chinn S., Pedoe H. D., Rose G. How well can we predict coronary heart disease? Findings in the United Kingdom Heart Disease Prevention Project. Br Med J 1984; 288: 1409–11
   PubMed Web of Science ®Google Scholar
• American Heart Association Committee on Reduction of Risk of Heart Attack and Stroke. Coronary risk handbook. Estimating risk of coronary heart disease in daily practice. American Heart Association, Dallas, TX 1973
   Google Scholar
• Stamler J., Epstein F. H. Coronary heart disease: risk factors as guides to preventive action. Prev Med 1972; 1: 27–48
   PubMedGoogle Scholar
• Gordon T., Garcia‐Palmieri M. R., Kagan A., Kannel W. B., Schiffman J. Differences in coronary heart disease in Framingham, Honolulu, and Puerto Rico. J Chronic Dis 1974; 27: 329–44
   PubMedGoogle Scholar
• Kottke T. E., Puska P., Salonen J., Tuomilehto J., Nissinen A. Projected population benefit from two cardiac risk factor modification strategies. Am J Epidemiol 1985; 121: 697–704
   PubMed Web of Science ®Google Scholar
• Marmot M., Wlnkelstein W. Epidemiologic observations on intervention trials for prevention of coronary heart disease. Am J Epidemiol 1975; 101: 177–81
   Google Scholar
• Rosenman R. H., Brand R. J., Sholtz Rl., Friedman M. Multivariate prediction of coronary heart disease during 8.5‐year follow‐up in the Western Collaborative Group Study. Am J Cardiol 1976; 37: 903–10
   PubMed Web of Science ®Google Scholar
• Menotti A., Capocaccia R., Farchi G., et al. The estimation of coronary heart disease incidence in a population from the risk function of another. Przegl Lek 1981; 38: 761–5
   Google Scholar
• Sacks S. T., Chiang C. L. A transition‐probability model for the study of chronic diseases. Mathematical Biosciences 1977; 34: 325–46
   Web of Science ®Google Scholar
• Moolgaukar S. H. I., Knudson A. G. Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Instit 1981; 66: 1037–52
   Google Scholar
• Keys A. Seven Countries. A Multivariate analysis of death and coronary heart disease. Harvard University Press, Cambridge, MA 1980
   Google Scholar
• Begg C. B., Gray R. Calculation of polychotomous logistic regression parameters using individualized regressions. Biometrika 1984; 71: 11–8
   Web of Science ®Google Scholar
• Tyroler H. A. Review of lipid‐lowering clinical trials in relation to observational epidemiologic studies. Circulation 1987; 76: 515–22
   PubMed Web of Science ®Google Scholar
• Committee of Principal Investigators. A co‐operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069–1118
   PubMedGoogle Scholar
• Lipid research clinics program. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–64
   PubMed Web of Science ®Google Scholar
• Frick M. H., Elo O., Haapa K., et al. Helsinki heart study: primary‐prevention trial with gemfibrozil in middle‐aged men with dyslipidemia. N Engl J Med. 1987; 317: 1237–45
   PubMed Web of Science ®Google Scholar
• Multiple risk factor intervention trial research group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982; 248: 1465–77
   PubMed Web of Science ®Google Scholar
• Dayton S., Pearce M. L., Hashimoto S., Dixon W. J., Tomiyasu U. A controlled clinical trial of a diet high in unsaturated fat. Monograph No. 25, American Heart Association, New York 1969
   Google Scholar
• Komitzer M., De Backer G., Dramaix M., Thilly C. The Belgian heart disease prevention project. Modification of the coronary risk profile in an industrial population. Circulation 1980; 61: 18–25
   Google Scholar
• Puska P., Salonen J. T., Nissinen A., et al. Change in risk factors for coronary heart disease during 10 years of a community intervention programme. The North Karelia Project. Br Med J 1983; 287: 1840–4
   PubMed Web of Science ®Google Scholar
• Hjermann I., Velve Byre K., Holme I., Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet 1981; ii: 1303–10
   Google Scholar
• The Lovastatin Study Group II. Therapeutic response to Lovastatin (mevinolin) in nonfamilial hypercholesterolemia. JAMA 1986; 256: 2829–34
   PubMed Web of Science ®Google Scholar
• Kottke T. E., Nissinen A., Puska P., Salonen J. T., Tuomilehto J. Message dissemination for a community‐based cardiovascular disease prevention programme. The North Karelia Project. Scand J Prim Health Care 1984; 2: 99–104
   Google Scholar
• Weinstein M. C., Statson W. B. Cost‐effectiveness of intervention to prevent or treat coronary heart disease. Ann Rev Public Health 1985; 6: 41–63
   Google Scholar
• Enholm C., Huttunen J. K., Pietinen P., et al. Effect of diet on serum lipoprotein in a population with a high risk of coronary heart disease. N Engl J Med 1982; 307: 850–5
   PubMed Web of Science ®Google Scholar
• Kannel W. B., Castelli W. P., Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 1979; 90: 85–91
   PubMed Web of Science ®Google Scholar
• Oster G., Epstein A. M. Cost‐effectiveness of antihyperli‐pemic therapy in the prevention of coronary heart disease. The case of cholestyramine. JAMA 1987; 258: 2381–7
   PubMed Web of Science ®Google Scholar
• Elveback L. R., Connolly D. C., Kurland L. T. Coronary heart disease in residents of Rochester, Minnesota. II. Mortality, incidence, and survivorship 1950–1975. Mayo Clin Proc 1981; 56: 665–72
   PubMed Web of Science ®Google Scholar
• Kottke T. E., Puska P., Salonen J. T., Tuomilehto J., Nissinen A. Changes in perceived heart disease risk and health during a community‐based heart disease prevention program: The North Karelia Project. AJPH 1984; 74: 1404–5
   PubMed Web of Science ®Google Scholar